Please assess the completion status of the following clinical trial:

Trial Title: Adjuvant Zoledronic Acid in High Risk Giant Cell Tumour of Bone (GCT)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Signed written informed consent~* Male or female \> 18 years of age~* Histologically proven GCT treated with surgery~* High risk GCT defined as minimal one or more of the following:~  * Recurrent GCT~ * GCT located in the pelvis, sacrum, spine, distal ulna or growth in soft tissue~ * GCT grade III~ * Pathological fracture in GCT~ * Absence of local adjuvant therapy (cryosurgery or phenol instillation)~* Neutrophils \> 1.5x109/L, platelets \> 100x109/L, and Hb \> 6 mmol/l~* Bilirubin level \< 1.5 x ULN~* ASAT and ALAT \< 2.5 x ULN~* Adequate renal function as defined by: serum creatinine clearance \> 60 cc/min~* Expected adequacy of follow-up~Exclusion Criteria:~* Unresectable or metastatic GCT and grade IV GCT~* Prior bisphosphonate usage, except preoperative treatment with zoledronic acid up to 3 months before surgery~* Other previous malignancy within 5 years, with exception of a history of a previous basal cell carcinoma of the skin or pre-invasive carcinoma of the cervix~* Known hypersensitivity reaction to any of the components of the treatment~* Pregnancy or lactating~* Medical or psychological condition which in the opinion of the investigator would not permit the patient to complete the study or sign meaningful informed consent

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Zoledronic acid (Type: EXPERIMENTAL): Adjuvant zoledronic acid
- Control (Type: NO_INTERVENTION): Standard care

Based on this trial design, predict the completion outcome and termination type (if applicable).